These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8726589)

  • 21. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer.
    De Rosa L; Lalle M; Pandolfi A; Pescador L
    Bone Marrow Transplant; 2001 May; 27(10):1031-5. PubMed ID: 11438817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
    Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
    Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mobilization of peripheral blood progenitor cells after induction chemotherapy (THP-doxorubicin-vinorelbine-cyclophosphamide-fluorouracil) and granulocyte colony-stimulating factor in breast cancer.
    Charrier S; Chassagne J; Curé H; Bay JO; Communal Y; Portefaix G; Ferrière JP; Bétail G; Plagne R; Chollet P
    Bone Marrow Transplant; 1998 Nov; 22(9):845-51. PubMed ID: 9827811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
    Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
    Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
    Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
    Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
    Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
    Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peripheral blood progenitor cell transplantation: economic issues.
    Yee GC
    Pharmacotherapy; 1998; 18(1 Pt 2):9S-16S. PubMed ID: 9473174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood.
    Gehling UM; Ryder JW; Hogan CJ; Hami L; McNiece I; Franklin W; Williams S; Helm K; King J; Shpall EJ
    Exp Hematol; 1997 Oct; 25(11):1125-39. PubMed ID: 9328449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
    Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
    Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of colony growth and hematologic engraftment in patients undergoing high-dose chemotherapy and autologous bone marrow transplantation for breast cancer.
    Meehan KR; Ericson SG; Tosteson TD; Mills LE
    Prog Clin Biol Res; 1994; 389():497-503. PubMed ID: 7535459
    [No Abstract]   [Full Text] [Related]  

  • 32. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver.
    Fisher DC; Vredenburgh JJ; Petros WP; Hussein A; Berry DA; Elkordy M; Rubin P; Gilbert CJ; Peters WP
    Bone Marrow Transplant; 1998 Jan; 21(2):117-22. PubMed ID: 9489626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields.
    Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y
    Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
    Weaver CH; Schulman KA; Buckner CD
    Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group.
    Bokemeyer C; Harstrick A; Beyer J; Metzner B; Rüther U; Hartmann JT; Holstein K; Derigs HG; de Wit R; Casper J; Schöffski P; Kührer I; Illiger HJ; Kempf B; Reichle A; Föller A; Hossfeld DK; Fischer JT; Berdel WE; Gerhartz HH; Kirchner H; Pflüger KH; Ostermann H; Kanz L; Schmoll HJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 4):24-32; discussion 45-8. PubMed ID: 9578059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood progenitor cell transplantation: impact on the pharmacy workload and budget.
    Davis TL
    Pharmacotherapy; 1998; 18(1 Pt 2):24S-29S. PubMed ID: 9473176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.